Lannett Company develops, manufactures, markets and distributes a broad spectrum of off-patent pharmaceutical products in a variety of dosage forms, including tablets, capsules, extended release, topicals, oral solutions and parenterals.
The company is committed to product development and has built a deep pipeline that includes a substantial number of product applications pending at the FDA in addition to a large number of product candidates in various stages of development. Lannett has grown substantially since 2001 and intends to further grow its business organically, as well as by acquiring complementary products or companies and forming strategic relationships.
The strategy for expanding its base generics business is to commercialize products in its pipeline, develop products with market barriers to entry, acquire complementary products and form strategic relationships. The company anticipates that the demand for its generic and branded medications will be fueled by, among other things, the aging Baby Boomer population. Lannett’s strong track record of regulatory compliance and manufacturing excellence, combined with strong management team, position the company well for the future.
